KSB 302Alternative Names: CBF-BS2; KSB302
Latest Information Update: 14 Jun 2002
At a glance
- Originator KS Biomedix Holdings
- Class Disease-modifying antirheumatics
- Mechanism of Action Glucose-6-phosphate dehydrogenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Rheumatoid arthritis